TScan Therapeutics Q2 EPS $(0.23) Misses $(0.21) Estimate, Sales $1.051M Miss $1.667M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 17.86 percent increase over losses of $(0.28) per share
TScan lost more money per share than experts thought it would, and sales came in much lower than expected. When a company misses on both fronts, it's a sign to watch whether they can turn things around or if problems are getting worse.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.